×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| Dr. Lal Pathlabs Limited | 6670.0 | 1293.0 | 6407.0 | 15.49 | 26,766 | 52.2 |
| PIRAMAL PHARMA LIMITED | 11508.0 | 1131.4 | 9698.8 | 0.85 | 26671 | 309.0 |
| Syngene International Limited | 8159.0 | 740.0 | 7993.0 | 1.83 | 26171 | 51.6 |
Dr. Lal Pathlabs Limited, with Security Code 539524, is a leading player in the Healthcare Service Provider industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 431.0 | 480.1 | 531.7 | 476.0 | 479.0 | 534.5 | 583.9 | 528.1 | 577.2 | 640.7 |
| Expenses | 315.3 | 344.3 | 368.7 | 345.9 | 348.7 | 379.0 | 399.4 | 382.7 | 418.1 | 457.3 |
| Operating Profit | 115.7 | 135.8 | 163.0 | 130.1 | 130.3 | 155.5 | 184.5 | 145.4 | 159.1 | 183.4 |
| OPM % | 26.84% | 28.29% | 30.66% | 27.33% | 27.2% | 29.09% | 31.6% | 27.53% | 27.56% | 28.62% |
| Other Income | 11.6 | 15.0 | 14.1 | 15.1 | 15.9 | 28.8 | 22.0 | 29.5 | 25.2 | 26.3 |
| Interest | 8.4 | 7.3 | 7.1 | 6.5 | 5.9 | 5.5 | 5.0 | 4.8 | 4.8 | 4.5 |
| Depreciation | 20.8 | 18.4 | 19.1 | 19.2 | 19.8 | 17.8 | 18.2 | 18.9 | 34.6 | 32.8 |
| Profit before tax | 98.1 | 125.1 | 150.9 | 119.5 | 120.5 | 161.0 | 183.3 | 151.2 | 144.9 | 172.4 |
| Tax % | -27.2% | -25.2% | -25.1% | -26.1% | -25.7% | -23.7% | -26.2% | 24.3% | 2.4% | 25% |
| Net Profit | 71.4 | 93.6 | 113.0 | 88.3 | 89.5 | 122.9 | 135.2 | 114.5 | 148.4 | 129.3 |
| EPS in Rs | 8.58 | 11.25 | 13.57 | 10.75 | 10.71 | 14.73 | 16.2 | 13.71 | 0 | 15.49 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 489.4 | 491.0 | 541.0 | 601.3 | 538.9 | 545.4 | 601.9 | 660.2 | 596.7 | 602.6 |
| Expenses | 376.4 | 375.4 | 394.8 | 423.5 | 398.3 | 400.7 | 431.9 | 457.7 | 442.7 | 433.6 |
| Operating Profit | 113.0 | 115.6 | 146.2 | 177.8 | 140.6 | 144.7 | 170.0 | 202.5 | 154.0 | 169.0 |
| OPM % | 23.09% | 23.54% | 27.02% | 29.57% | 26.09% | 26.53% | 28.24% | 30.67% | 25.81% | 28.05% |
| Other Income | 10.5 | 14.2 | 14.4 | 18.1 | 18.3 | 18.4 | 20.6 | 21.9 | 25.1 | 25.8 |
| Interest | 9.1 | 9.0 | 8.0 | 7.8 | 7.0 | 6.6 | 6.0 | 6.0 | 5.3 | 5.0 |
| Depreciation | 37.9 | 37.6 | 35.1 | 35.9 | 36.0 | 36.6 | 34.7 | 35.3 | 35.5 | 36.4 |
| Profit before tax | 76.5 | 83.2 | 117.5 | 152.2 | 115.9 | 119.9 | 149.9 | 183.1 | 138.3 | 153.4 |
| Tax % | -29.9% | -31.6% | -28.9% | -27.3% | -29.1% | -28.4% | 28.1% | 28.6% | -29.1% | 1.4% |
| Net Profit | 53.6 | 56.9 | 83.6 | 110.7 | 82.2 | 85.8 | 107.8 | 130.8 | 98.1 | 155.5 |
| EPS in Rs | 6.35 | 6.82 | 9.93 | 13.12 | 9.76 | 10.12 | 12.76 | 15.48 | 11.58 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 13% |
| 3 Years: | 8% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 17% |
| 3 Years: | 13% |
| TTM: | 29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 14% |
| 3 Years: | 13% |
| 1 Year: | 10% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 13% |
| 3 Years: | 6% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 17% |
| 3 Years: | 12% |
| TTM: | 36% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 14% |
| 3 Years: | 13% |
| 1 Year: | 10% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|